{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:17:45Z","timestamp":1791285465983,"version":"4.1.0"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40620-018-0547-6","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T04:25:50Z","timestamp":1541564750000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tuberous sclerosis complex: new insights into clinical and therapeutic approach"],"prefix":"10.1093","volume":"32","author":[{"given":"Angela","family":"Volpi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Labriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Righetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"key":"547_CR1","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(05)78872-3","volume":"351","author":"FJ O\u2019Callaghan","year":"1998","unstructured":"O\u2019Callaghan FJ, Shiell AW, Osborne JP, Martyn CN (1998) Prevalence of tuberous sclerosis estimated by capture\u2013recapture analysis. Lancet 351:1490","journal-title":"Lancet"},{"key":"547_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1464-410X.2004.05046.x","volume":"94","author":"FJ O\u2019Callaghan","year":"2004","unstructured":"O\u2019Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP (2004) An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 94:853\u2013857","journal-title":"BJU Int"},{"key":"547_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1378\/chest.14-3095","volume":"148","author":"AS Kristof","year":"2015","unstructured":"Kristof AS, Li PZ, Major P, Landry JS (2015) Lymphangioleiomyomatosis and tuberous sclerosis complex in Quebec: prevalence and health-care utilization. Chest 148:444\u2013449","journal-title":"Chest"},{"key":"547_CR4","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1148\/rg.e32","volume":"28","author":"S Umeoka","year":"2008","unstructured":"Umeoka S et al (2008) Pictorial review of tuberous sclerosis in various organs. Radiographics 28:e32","journal-title":"Radiographics"},{"key":"547_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","volume":"57","author":"RA Schwartz","year":"2007","unstructured":"Schwartz RA, Fern\u00e1ndez G, Kotulska K, J\u00f3\u017awiak S (2007) Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57:189\u2013202","journal-title":"J Am Acad Dermatol"},{"key":"547_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/302381","volume":"64","author":"AC Jones","year":"1999","unstructured":"Jones AC et al (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64:1305\u20131315","journal-title":"Am J Hum Genet"},{"key":"547_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","volume":"47","author":"CC Dibble","year":"2012","unstructured":"Dibble CC et al (2012) TBC1D7 is a third subunit of the TSC1\u2013TSC2 complex upstream of mTORC1. Mol Cell 47:535\u2013546","journal-title":"Mol Cell"},{"key":"547_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0092-8674(01)00332-4","volume":"105","author":"N Tapon","year":"2001","unstructured":"Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345\u2013355","journal-title":"Cell"},{"key":"547_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1212\/01.wnl.0000280579.04974.c0","volume":"70","author":"FE Jansen","year":"2008","unstructured":"Jansen FE et al (2008) Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 70:916\u2013923","journal-title":"Neurology"},{"key":"547_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.paed.2007.10.013","volume":"18","author":"F O\u2019Callaghan","year":"2008","unstructured":"O\u2019Callaghan F (2008) Tuberous sclerosis complex. Paediatr Child Health (Oxford) 18:30\u201336","journal-title":"Paediatr Child Health (Oxford)"},{"key":"547_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0883073812448437","volume":"28","author":"B Lennert","year":"2013","unstructured":"Lennert B, Farrelly E, Sacco P, Pira G, Frost M (2013) Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. J Child Neurol 28:461\u2013469","journal-title":"J Child Neurol"},{"key":"547_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3111\/13696998.2015.1075995","volume":"18","author":"F Vekeman","year":"2015","unstructured":"Vekeman F et al (2015) Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J Med Econ 18:1060\u20131070","journal-title":"J Med Econ"},{"key":"547_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson","year":"1971","unstructured":"Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820\u2013823","journal-title":"Proc Natl Acad Sci USA"},{"key":"547_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/hmg\/3.10.1829","volume":"3","author":"C Carbonara","year":"1994","unstructured":"Carbonara C et al (1994) 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet 3:1829\u20131832","journal-title":"Hum Mol Genet"},{"key":"547_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ng0294-193","volume":"6","author":"AJ Green","year":"1994","unstructured":"Green AJ, Smith M, Yates JR (1994) Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 6:193\u2013196","journal-title":"Nat Genet"},{"key":"547_CR16","first-page":"1639","volume":"151","author":"EP Henske","year":"1997","unstructured":"Henske EP et al (1997) Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151:1639\u20131647","journal-title":"Am J Pathol"},{"key":"547_CR17","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/WNL.0b013e3181e04325","volume":"74","author":"PB Crino","year":"2010","unstructured":"Crino PB, Aronica E, Baltuch G, Nathanson KL (2010) Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74:1716\u20131723","journal-title":"Neurology"},{"key":"547_CR18","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/hmg\/6.13.2265","volume":"6","author":"J Yates","year":"1997","unstructured":"Yates J (1997) Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum Mol Genet 6:2265\u20132269","journal-title":"Hum Mol Genet"},{"key":"547_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1086\/302322","volume":"64","author":"VM Rose","year":"1999","unstructured":"Rose VM et al (1999) Germ-line mosaicism in tuberous sclerosis: how common? Am J Hum Genet 64:986\u2013992","journal-title":"Am J Hum Genet"},{"key":"547_CR20","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1086\/302412","volume":"64","author":"S Verhoef","year":"1999","unstructured":"Verhoef S et al (1999) High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 64:1632\u20131637","journal-title":"Am J Hum Genet"},{"key":"547_CR21","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.2353\/ajpath.2009.080799","volume":"174","author":"E Lesma","year":"2009","unstructured":"Lesma E et al (2009) The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am J Pathol 174:2150\u20132159","journal-title":"Am J Pathol"},{"key":"547_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/jcmm.12237","volume":"18","author":"E Lesma","year":"2014","unstructured":"Lesma E et al (2014) TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival. J Cell Mol Med 18:766\u2013779","journal-title":"J Cell Mol Med"},{"key":"547_CR23","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.transproceed.2008.10.009","volume":"40","author":"MN Hall","year":"2008","unstructured":"Hall MN (2008) mTOR-what does it do? Transplant Proc 40:S5\u2013S8","journal-title":"Transplant Proc"},{"key":"547_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.pediatrneurol.2013.12.002","volume":"50","author":"K J\u00fclich","year":"2014","unstructured":"J\u00fclich K, Sahin M (2014) Mechanism-based treatment in tuberous sclerosis complex. Pediatr Neurol 50:290\u2013296","journal-title":"Pediatr Neurol"},{"key":"547_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259\u20131268","journal-title":"Curr Biol"},{"key":"547_CR26","doi-asserted-by":"publisher","first-page":"13571","DOI":"10.1073\/pnas.202476899","volume":"99","author":"AR Tee","year":"2002","unstructured":"Tee AR et al (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571\u201313576","journal-title":"Proc Natl Acad Sci USA"},{"key":"547_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","volume":"52","author":"P Curatolo","year":"2015","unstructured":"Curatolo P (2015) Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 52:281\u2013289","journal-title":"Pediatr Neurol"},{"key":"547_CR28","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.1038\/sj.onc.1209090","volume":"24","author":"A Astrinidis","year":"2005","unstructured":"Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24:7475\u20137481","journal-title":"Oncogene"},{"key":"547_CR29","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1158\/0008-5472.CAN-06-1740","volume":"66","author":"C Wilson","year":"2006","unstructured":"Wilson C et al (2006) Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+\/\u2212 mice. Cancer Res 66:7934\u20137938","journal-title":"Cancer Res"},{"key":"547_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147\u2013158","journal-title":"Cancer Cell"},{"key":"547_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ (2015) Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 14:733\u2013745","journal-title":"Lancet Neurol"},{"key":"547_CR32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejpn.2015.11.011","volume":"20","author":"C Kingswood","year":"2016","unstructured":"Kingswood C et al (2016) The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Eur J Paediatr Neurol 20:296\u2013308","journal-title":"Eur J Paediatr Neurol"},{"key":"547_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.pediatrneurol.2012.02.015","volume":"46","author":"MH Kohrman","year":"2012","unstructured":"Kohrman MH (2012) Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol 46:267\u2013275","journal-title":"Pediatr Neurol"},{"key":"547_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0387-7604(98)00022-9","volume":"20","author":"Y Inoue","year":"1998","unstructured":"Inoue Y et al (1998) CT and MR imaging of cerebral tuberous sclerosis. Brain Dev 20:209\u2013221","journal-title":"Brain Dev"},{"key":"547_CR35","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00381-014-2555-8","volume":"30","author":"K Kotulska","year":"2014","unstructured":"Kotulska K et al (2014) Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Childs Nerv Syst 30:2037\u20132042","journal-title":"Childs Nerv Syst"},{"key":"547_CR36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.spen.2015.10.003","volume":"22","author":"S J\u00f3\u017awiak","year":"2015","unstructured":"J\u00f3\u017awiak S, Mandera M, M\u0142ynarski W (2015) Natural history and current treatment options for subependymal giant cell astrocytoma in tuberous sclerosis complex. Semin Pediatr Neurol 22:274\u2013281","journal-title":"Semin Pediatr Neurol"},{"key":"547_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.rcl.2015.12.003","volume":"54","author":"A Krishnan","year":"2016","unstructured":"Krishnan A, Kaza RK, Vummidi DR (2016) Cross-sectional imaging review of tuberous sclerosis. Radiol Clin N Am 54:423\u2013440","journal-title":"Radiol Clin N Am"},{"key":"547_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1469-8749.1996.tb12086.x","volume":"38","author":"DW Webb","year":"1996","unstructured":"Webb DW, Fryer AE, Osborne JP (1996) Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 38:146\u2013155","journal-title":"Dev Med Child Neurol"},{"key":"547_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","volume":"15","author":"S J\u00f3\u017awiak","year":"2011","unstructured":"J\u00f3\u017awiak S et al (2011) Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 15:424\u2013431","journal-title":"Eur J Paediatr Neurol"},{"key":"547_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1046\/j.1365-4362.1998.00495.x","volume":"37","author":"S J\u00f3z\u00b0wiak","year":"1998","unstructured":"J\u00f3z\u00b0wiak S, Schwartz RA, Janniger CK, Micha\u0142owicz R, Chmielik J (1998) Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 37:911\u2013917","journal-title":"Int J Dermatol"},{"key":"547_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.1996.tb03597.x","volume":"135","author":"DW Webb","year":"1996","unstructured":"Webb DW, Clarke A, Fryer A, Osborne JP (1996) The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 135:1\u20135","journal-title":"Br J Dermatol"},{"key":"547_CR42","first-page":"25","volume":"6","author":"SH Tonekaboni","year":"2012","unstructured":"Tonekaboni SH et al (2012) Clinical and para clinical manifestations of tuberous sclerosis: a cross sectional study on 81 pediatric patients. Iran J Child Neurol 6:25\u201331","journal-title":"Iran J Child Neurol"},{"key":"547_CR43","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-2230.1985.tb00623.x","volume":"10","author":"SD Bell","year":"1985","unstructured":"Bell SD, MacDonald DM (1985) The prevalence of cafe-au-lait patches in tuberous sclerosis. Clin Exp Dermatol 10:562\u2013565","journal-title":"Clin Exp Dermatol"},{"key":"547_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2015.12.008","volume":"158","author":"LM Moir","year":"2016","unstructured":"Moir LM, Lymphangioleiomyomatosis (2016) Current understanding and potential treatments. Pharmacol Ther 158:114\u2013124","journal-title":"Pharmacol Ther"},{"key":"547_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CLEP.S50780","volume":"7","author":"AM Taveira-DaSilva","year":"2015","unstructured":"Taveira-DaSilva AM, Moss J (2015) Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 7:249\u2013257","journal-title":"Clin Epidemiol"},{"key":"547_CR46","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","volume":"97","author":"T Carsillo","year":"2000","unstructured":"Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97:6085\u20136090","journal-title":"Proc Natl Acad Sci USA"},{"key":"547_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7863\/jum.2001.20.1.63","volume":"20","author":"R Axt-Fliedner","year":"2001","unstructured":"Axt-Fliedner R et al (2001) Prenatal diagnosis of cerebral lesions and multiple intracardiac rhabdomyomas in a fetus with tuberous sclerosis. J Ultrasound Med 20:63\u201367","journal-title":"J Ultrasound Med"},{"key":"547_CR48","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/01.ju.0000058253.40352.60","volume":"169","author":"TS Lendvay","year":"2003","unstructured":"Lendvay TS, Marshall FF (2003) The tuberous sclerosis complex and its highly variable manifestations. J Urol 169:1635\u20131642","journal-title":"J Urol"},{"key":"547_CR49","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1067\/mva.2001.111976","volume":"33","author":"CJ Jost","year":"2001","unstructured":"Jost CJ et al (2001) Aortic aneurysms in children and young adults with tuberous sclerosis: report of two cases and review of the literature. J Vasc Surg 33:639\u2013642","journal-title":"J Vasc Surg"},{"key":"547_CR50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0022-5347(17)43234-4","volume":"138","author":"TJ Stillwell","year":"1987","unstructured":"Stillwell TJ, Gomez MR, Kelalis PP (1987) Renal lesions in tuberous sclerosis. J Urol 138:477\u2013481","journal-title":"J Urol"},{"key":"547_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1464-410X.1994.tb16577.x","volume":"74","author":"DW Webb","year":"1994","unstructured":"Webb DW, Kabala J, Osborne JP (1994) A population study of renal disease in patients with tuberous sclerosis. Br J Urol 74:151\u2013154","journal-title":"Br J Urol"},{"key":"547_CR52","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/000992289603501001","volume":"35","author":"AR O\u2019Hagan","year":"1996","unstructured":"O\u2019Hagan AR, Ellsworth R, Secic M, Rothner AD, Brouhard BH (1996) Renal manifestations of tuberous sclerosis complex. Clin Pediatr (Phila) 35:483\u2013489","journal-title":"Clin Pediatr (Phila)"},{"key":"547_CR53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","volume":"66","author":"CW Shepherd","year":"1991","unstructured":"Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66:792\u2013796","journal-title":"Mayo Clin Proc"},{"key":"547_CR54","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/jmg.33.6.480","volume":"33","author":"JA Cook","year":"1996","unstructured":"Cook JA, Oliver K, Mueller RF, Sampson J (1996) A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 33:480\u2013484","journal-title":"J Med Genet"},{"key":"547_CR55","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","volume":"70","author":"SK Rakowski","year":"2006","unstructured":"Rakowski SK et al (2006) Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 70:1777\u20131782","journal-title":"Kidney Int"},{"key":"547_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.crad.2009.09.014","volume":"65","author":"D Halpenny","year":"2010","unstructured":"Halpenny D, Snow A, McNeill G, Torreggiani WC (2010) The radiological diagnosis and treatment of renal angiomyolipoma\u2014current status. Clin Radiol 65:99\u2013108","journal-title":"Clin Radiol"},{"key":"547_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0022-5347(01)63072-6","volume":"160","author":"DH Ewalt","year":"1998","unstructured":"Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES (1998) Renal lesion growth in children with tuberous sclerosis complex. J Urol 160:141\u2013145","journal-title":"J Urol"},{"key":"547_CR58","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3349\/ymj.2010.51.5.728","volume":"51","author":"KC Koo","year":"2010","unstructured":"Koo KC et al (2010) Trends of presentation and clinical outcome of treated renal angiomyolipoma. Yonsei Med J 51:728\u2013734","journal-title":"Yonsei Med J"},{"key":"547_CR59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1148\/radiol.2251011477","volume":"225","author":"K Yamakado","year":"2002","unstructured":"Yamakado K et al (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78\u201382","journal-title":"Radiology"},{"key":"547_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.urology.2015.12.009","volume":"89","author":"A Kapoor","year":"2016","unstructured":"Kapoor A et al (2016) Evolving strategies in the treatment of tuberous sclerosis complex-associated angiomyolipomas (TSC-AML). Urology 89:19\u201326","journal-title":"Urology"},{"key":"547_CR61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ndt\/10.3.349","volume":"10","author":"HP Neumann","year":"1995","unstructured":"Neumann HP et al (1995) Tuberous sclerosis complex with end-stage renal failure. Nephrol Dial Transplant 10:349\u2013353","journal-title":"Nephrol Dial Transplant"},{"key":"547_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/ndt\/11.3.481","volume":"11","author":"F Schillinger","year":"1996","unstructured":"Schillinger F, Montagnac R (1996) Chronic renal failure and its treatment in tuberous sclerosis. Nephrol Dial Transplant 11:481\u2013485","journal-title":"Nephrol Dial Transplant"},{"key":"547_CR63","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/ndt\/14.4.988","volume":"14","author":"A Clarke","year":"1999","unstructured":"Clarke A, Hancock E, Kingswood C, Osborne JP (1999) End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant 14:988\u2013991","journal-title":"Nephrol Dial Transplant"},{"key":"547_CR64","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49:243\u2013254 (2013)","journal-title":"Pediatr Neurol"},{"key":"547_CR65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49:255\u2013265 (2013)","journal-title":"Pediatr Neurol"},{"key":"547_CR66","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/ijms17050735","volume":"17","author":"S Granata","year":"2016","unstructured":"Granata S et al (2016) Sirolimus and everolimus pathway: reviewing candidate genes influencing their intracellular effects. Int J Mol Sci 17:735","journal-title":"Int J Mol Sci"},{"key":"547_CR67","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817\u2013824","journal-title":"Lancet"},{"key":"547_CR68","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/157015912804499537","volume":"10","author":"P Curatolo","year":"2012","unstructured":"Curatolo P, Moavero R (2012) mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol 10:404\u2013415","journal-title":"Curr Neuropharmacol"},{"key":"547_CR69","doi-asserted-by":"publisher","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora SL et al (2011) Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 6:e23379","journal-title":"PLoS One"},{"key":"547_CR70","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM et al (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17:4071\u20134081","journal-title":"Clin Cancer Res"},{"key":"547_CR71","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801\u20131811","journal-title":"N Engl J Med"},{"key":"547_CR72","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz DN et al (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490\u2013498","journal-title":"Ann Neurol"},{"key":"547_CR73","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1016\/j.transproceed.2009.06.227","volume":"41","author":"A Tarasewicz","year":"2009","unstructured":"Tarasewicz A et al (2009) Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 41:3577\u20133582","journal-title":"Transplant Proc"},{"key":"547_CR74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13023-015-0317-7","volume":"10","author":"TH Sasongko","year":"2015","unstructured":"Sasongko TH, Ismail NFD, Nik Abdul Malik NMA, Zabidi-Hussin ZAMH (2015) Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex-associated tumors: a systematic review on non-randomized studies using meta-analysis. Orphanet J Rare Dis 10:95","journal-title":"Orphanet J Rare Dis"},{"key":"547_CR75","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/pbc.25368","volume":"62","author":"J Trelinska","year":"2015","unstructured":"Trelinska J et al (2015) Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. Pediatr Blood Cancer 62:616\u2013621","journal-title":"Pediatr Blood Cancer"},{"key":"547_CR76","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00381-013-2170-0","volume":"29","author":"AM Cappellano","year":"2013","unstructured":"Cappellano AM et al (2013) Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst 29:2301\u20132305","journal-title":"Childs Nerv Syst"},{"key":"547_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.18632\/aging.100298","volume":"3","author":"P Major","year":"2011","unstructured":"Major P (2011) Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 3:189\u2013191","journal-title":"Aging (Albany NY)"},{"key":"547_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125\u2013132","journal-title":"Lancet"},{"key":"547_CR79","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger DA et al (2013) Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80:574\u2013580","journal-title":"Neurology"},{"key":"547_CR80","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388:2153\u20132163","journal-title":"Lancet"},{"key":"547_CR81","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1097\/01.TP.0000162433.34739.61","volume":"79","author":"J Pascual","year":"2005","unstructured":"Pascual J, Marc\u00e9n R, Ortu\u00f1o J (2005) Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 79:S80\u2013S84","journal-title":"Transplantation"},{"key":"547_CR82","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","volume":"52","author":"I Goyer","year":"2015","unstructured":"Goyer I, Dahdah N, Major P (2015) Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol 52:450\u2013453","journal-title":"Pediatr Neurol"},{"key":"547_CR83","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.pharep.2016.01.005","volume":"68","author":"K Sadowski","year":"2016","unstructured":"Sadowski K, Kotulska K, J\u00f3\u017awiak S (2016) Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep 68:536\u2013542","journal-title":"Pharmacol Rep"},{"key":"547_CR84","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","volume":"28","author":"B Kaplan","year":"2014","unstructured":"Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 28:126\u2013133","journal-title":"Transplant Rev (Orlando)"},{"key":"547_CR85","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.oooo.2014.08.023","volume":"119","author":"E-M Kalogirou","year":"2015","unstructured":"Kalogirou E-M, Tosios KI, Piperi EP, Sklavounou A (2015) mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. Oral Surg Oral Med Oral Pathol Oral Radiol 119:e13\u2013e19","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"547_CR86","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1016\/j.transproceed.2010.06.023","volume":"42","author":"T Sasaoka","year":"2010","unstructured":"Sasaoka T et al (2010) Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients. Transplant Proc 42:3700\u20133703","journal-title":"Transplant Proc"},{"key":"547_CR87","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11523-014-0310-4","volume":"9","author":"AECAB Willemsen","year":"2014","unstructured":"Willemsen AECAB et al (2014) Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol 9:287\u2013291","journal-title":"Target Oncol"},{"key":"547_CR88","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1093\/ndt\/gfn401","volume":"23","author":"S Alexandru","year":"2008","unstructured":"Alexandru S et al (2008) Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 23:3353\u20133355","journal-title":"Nephrol Dial Transplant"},{"key":"547_CR89","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.transproceed.2009.06.003","volume":"41","author":"A Rodr\u00edguez-Moreno","year":"2009","unstructured":"Rodr\u00edguez-Moreno A et al (2009) Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 41:2163\u20132165","journal-title":"Transplant Proc"},{"key":"547_CR90","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-013-2681-0","volume":"141","author":"E Teplinsky","year":"2013","unstructured":"Teplinsky E et al (2013) Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat 141:167\u2013172","journal-title":"Breast Cancer Res Treat"},{"key":"547_CR91","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/jdv.12662","volume":"29","author":"L Atzori","year":"2015","unstructured":"Atzori L, Conti B, Zucca M, Pau M (2015) Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients. J Eur Acad Dermatol Venereol 29:1626\u20131630","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"547_CR92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","volume":"26","author":"J Trelinska","year":"2015","unstructured":"Trelinska J et al (2015) Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs 26:437\u2013442","journal-title":"Anticancer Drugs"},{"key":"547_CR93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","volume":"26","author":"F Diekmann","year":"2012","unstructured":"Diekmann F, Andr\u00e9s A, Oppenheimer F (2012) mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 26:27\u201329","journal-title":"Transplant Rev (Orlando)"},{"key":"547_CR94","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/TP.0b013e318211d342","volume":"91","author":"G Stallone","year":"2011","unstructured":"Stallone G et al (2011) Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91:997\u20131004","journal-title":"Transplantation"},{"key":"547_CR95","doi-asserted-by":"publisher","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","volume":"296","author":"B Vollenbr\u00f6ker","year":"2009","unstructured":"Vollenbr\u00f6ker B et al (2009) mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Ren Physiol 296:F418\u2013F426","journal-title":"Am J Physiol Ren Physiol"},{"key":"547_CR96","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","volume":"66","author":"MJC Eijkemans","year":"2015","unstructured":"Eijkemans MJC et al (2015) Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis 66:638\u2013645","journal-title":"Am J Kidney Dis"},{"key":"547_CR97","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.ejrad.2011.06.003","volume":"81","author":"A Chatziioannou","year":"2012","unstructured":"Chatziioannou A et al (2012) Transcatheter arterial embolization as therapy of renal angiomyolipomas: the evolution in 15 years of experience. Eur J Radiol 81:2308\u20132312","journal-title":"Eur J Radiol"},{"key":"547_CR98","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12098-012-0716-x","volume":"80","author":"V Pasquale De","year":"2013","unstructured":"De Pasquale V et al (2013) Selective arterial embolization of giant renal tuberous sclerosis. Indian J Pediatr 80:263\u2013265","journal-title":"Indian J Pediatr"},{"key":"547_CR99","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1097\/01.ju.0000177497.31986.64","volume":"174","author":"DH Ewalt","year":"2005","unstructured":"Ewalt DH et al (2005) Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol 174:1764\u20131766","journal-title":"J Urol"},{"key":"547_CR100","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/qims.2017.01.02","volume":"7","author":"F Bardin","year":"2017","unstructured":"Bardin F et al (2017) Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction. Quant Imaging Med Surg 7:8\u201323","journal-title":"Quant Imaging Med Surg"},{"key":"547_CR101","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1177\/0300060516684251","volume":"45","author":"C Wang","year":"2017","unstructured":"Wang C et al (2017) Transarterial embolization for renal angiomyolipomas: a single centre experience in 79 patients. J Int Med Res 45:706\u2013713","journal-title":"J Int Med Res"},{"key":"547_CR102","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00270-015-1201-5","volume":"39","author":"M Cristescu","year":"2016","unstructured":"Cristescu M et al (2016) Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Interv Radiol 39:433\u2013440","journal-title":"Cardiovasc Interv Radiol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-018-0547-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-018-0547-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-018-0547-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:07Z","timestamp":1777564567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/32\/3\/355\/8328147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1007\/s40620-018-0547-6","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"24 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical committee of San Paolo Hospital approved data analysis of TSC patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}